SCHEMBL2151759

SCHEMBL2151759

Nc1ccc(N2CCSCC2)c(F)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.61
▸ MAPT P10636 6/20 0.61
▸ GFER P55789 3/20 0.61
▸ LMNA P02545 1/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ LGMN Q99538 2/20 0.50
▸ ALOX15 P16050 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ MAPK10 P53779 1/20 0.50
▸ POLB P06746 1/20 0.43
▸ GAA P10253 4/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ THRB P10828 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ NR4A1 P22736 1/20 0.42
▸ PTK2B Q14289 1/20 0.42
▸ MAOA P21397 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29665277 1.00 ALDH1A1 (0.61) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL18396814 0.94 ALDH1A1 (0.55) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL18396740 0.90 ALDH1A1 (0.58) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL17265648 0.87 ALDH1A1 (0.77) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL3442442 0.83 ALDH1A1 (0.67) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL7038110 0.83 ALDH1A1 (0.67) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL30721891 0.81 ALDH1A1 (0.65) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL4918379 0.81 ALDH1A1 (0.65) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL157935 0.81 ALDH1A1 (0.65) ALDH1A1MAPTGFERLMNAMAPK1
SCHEMBL28901605 0.80 ALDH1A1 (0.63) ALDH1A1MAPTGFERLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119768002-A Perovskite solar cell and preparation method thereof 中国华能集团清洁能源技术研究院有限公司 2025-04-04 — — CN claimed
CN-119768002-A Perovskite solar cell and preparation method thereof 中国华能集团清洁能源技术研究院有限公司 2025-04-04 — — CN disclosed
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC (US) 2023-03-02 — — US disclosed
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC (US) 2023-03-02 — — US disclosed
US-11174252-B2 Heterocyclic compounds as kinase inhibitors NUVATION BIO INC. (US) 2021-11-16 — — US disclosed
US-11174252-B2 Heterocyclic compounds as kinase inhibitors NUVATION BIO INC. (US) 2021-11-16 — — US disclosed
CN-112334451-A Heterocyclic compounds as kinase inhibitors 诺维逊生物股份有限公司 2021-02-05 — — CN disclosed
US-20190248774-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-08-15 — — US disclosed
US-20190248774-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-08-15 — — US disclosed
EP-2875001-B1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS SUNSHINE LAKE PHARMA CO LTD (CN) 2019-01-09 — — EP disclosed
US-6919329-B2 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY (US) 2005-07-19 — — US disclosed
US-6914058-B2 1-(p-(thiomorpholino)phenyl)-1,2,3-triazole derivatives DR. REDDY'S LABORATORIES, LIMITED (IN) 2005-07-05 — — US disclosed
US-20050113347-A1 NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LIMITED 2005-05-26 — — US disclosed
EP-1478629-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2004-11-24 — — EP disclosed
EP-1467977-A1 NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. Dr. Reddy's Laboratories Ltd. (IN) 2004-10-20 — — EP disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 — — US disclosed
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-03-04 — — US disclosed
US-20040014967-A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound PHARMACIA & UPJOHN COMPANY 2004-01-22 — — US disclosed
WO-2003072553-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 — — WO disclosed
WO-2003059894-A1 NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. DR.REDDY'S LABORATORIES LTD. (IN) 2003-07-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174252-B2 Heterocyclic compounds as kinase inhibitors CDK6, CDK4, CDK9 ALDH1A1 2534/4885MAPT 3390/4885GFER 3536/4885
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 ALDH1A1 956/4885MAPT 4491/4885GFER 3037/4885
US-20190248774-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 ALDH1A1 2992/4885MAPT 3156/4885GFER 3743/4885
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 ALDH1A1 956/4885MAPT 4491/4885GFER 3037/4885
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 ALDH1A1 2992/4885MAPT 3156/4885GFER 3743/4885
US-20040014967-A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound AADAC, AAAS, SLC7A1 ALDH1A1 1622/4885MAPT 1484/4885GFER 1972/4885
US-20050113347-A1 NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP3A4, CYP3A43, CYP3A5 ALDH1A1 2745/4885MAPT 48/4885GFER 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback